Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05156905
Title Phase 2 Trial of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
Recruitment Not yet recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors University of California, San Diego

prostate adenocarcinoma


Cirmtuzumab + Docetaxel

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.